CARDIFF ONCOLOGY, INC. Deferred Tax Assets, Gross
CARDIFF ONCOLOGY, INC. (CRDF) had Deferred Tax Assets, Gross of $57.40 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Gross $57.40M.
- 2024-12-31: Deferred Tax Assets, Gross $48.69M.
- 2023-12-31: Deferred Tax Assets, Gross $39.55M.
- 2022-12-31: Deferred Tax Assets, Gross $30.57M.
| Period end | Deferred Tax Assets, Gross | Deferred Tax Assets, Gross as first filed |
|---|---|---|
| 2025-12-31 | $57.40M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $48.69M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $39.55M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $30.57M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $22.44M 10-K · filed 2023-03-02 | $54.65M 10-K · filed 2022-02-24 |
| 2020-12-31 | $48.03M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $43.99M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |